Bergabunglah dengan Buletin Kami
Bergabunglah dengan daftar pelanggan kami untuk mendapatkan artikel terkini, update dan penawaran khusus langsung di kotak masuk Anda
As of this week in Montana, any biotech company with an experimental drug has a ...
LTG-001 achieved the primary endpoint of the Phase IIb LTG-001-010 trial (NCT071...
Elix and the University of Vienna will partner to bridge the gap between advance...
The collaboration brings together Celonic’s expertise in cell line development, ...
A Phase III trial found the donor-derived cell therapy deramiocel slowed arm mus...
By precisely altering the huntingtin gene rather than switching it off, an in vi...
A GWAS meta-analysis including 2.5 million individuals identified 26 genetic ris...
In a new publishing deal, Causaly and Sage have announced a partnership to bring...
The researchers identified Nys34 as a leading candidate after it demonstrated th...
Manufacturing costs for therapies based on adeno-associated viruses (AAV) could ...
NIBRT predicts that the market for GLP-1 receptor agonist-based diabetes and obe...
Modular flow-through and pseudo-affinity downstream processing technologies enab...
A new perfusion-bioreactor platform developed by researchers in France offers ti...
In a new publishing deal, Causaly and Sage have announced a partnership to bring...
The addition of NanoCellect's technology advances Nova’s strategy of offering a ...
Earlier this month Forte announced positive results for its lead candidate FB102...
